IDH1 and acute myeloid leukemia: In terms of therapeutic decision-making for elderly or unfit AML patients with known FLT3 or IDH1/2 mutations, we are often faced with the choice of venetoclax-based therapy or targeted therapy with either IDH inhibitors (enasidenib/ivosidenib) or FLT3 inhibitors (midostaurin/gilteritinib).